Company Filing History:
Years Active: 2019
Title: Innovations by Kenneth Christopher Thornton in Antibody Derivatives
Introduction
Kenneth Christopher Thornton, based in Seattle, WA, is a notable inventor in the field of biopharmaceuticals. With a focus on antibody derivatives, Thornton has made significant contributions to medical therapies through his innovative inventions. His expertise and dedication to research have led to the development of a patented construct that addresses critical medical needs.
Latest Patents
Kenneth Thornton holds one patent, which pertains to antibody derivatives. The patent describes a bivalent, bispecific construct that comprises an anti-IL-6 antibody, or its derivative, and an anti-IL-23 antibody, or its derivative. This innovative design not only emphasizes the utility of these antibodies in therapy but also specifies their applications, making significant strides in treatment methodologies for various conditions.
Career Highlights
Thornton is affiliated with MedImmune Limited, a renowned biopharmaceutical company that specializes in developing innovative therapies. His work at MedImmune has enabled him to collaborate with leading scientists and contribute to advancements in the understanding and treatment of immune-mediated disorders.
Collaborations
Throughout his career, Kenneth Thornton has worked alongside notable colleagues, including Kenneth H. Grabstein and William Brady. These collaborations have been crucial in fostering an environment of innovation and enhancing the development of therapeutic strategies in the field.
Conclusion
Kenneth Christopher Thornton's contributions to the realm of antibody derivatives showcase his commitment to advancing medical therapies. With his patented invention and collaboration with fellow scientists, he continually enhances the potential for better health outcomes and signifies the importance of innovation in biopharmaceutical research.